KEY WORDS: AHA Scientific Statements antiplatelet therapy focused update glycoprotein IIb/IIIa inhibitors myocardial infarction non ST elevation percutaneous coronary intervention thienopyridines P2Y12 receptor inhibitor unstable angina Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update) Committee Member Employment Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Hani Jneid, Chair Baylor College of Medicine The Michael E. DeBakey VA Medical Center Assistant Professor of Medicine None None None None None None None Jeffrey L. Anderson, Vice Chair Intermountain Medical Center Associate Chief of Cardiology AstraZeneca None None None None None 3.2.1 R. Scott Wright, Vice Chair Mayo Clinic Professor of Medicine and Consultant in Cardiology Hoffman LaRoche None None None None None None Cynthia D. Adams Community Health Network/The Indiana Heart Hospital Supervisor None None None None None None None Charles R. Bridges University of Pennsylvania Medical Center Chief, Cardiothoracic Surgery, Pennsylvania Hospital; Associate Professor of Surgery AstraZeneca Bayer Pharmaceuticals None None None None 3.2.1 Donald E. Casey, Jr Atlantic Health Vice President of Quality and Chief Medical Officer None None None None None None None Steven M. Ettinger Pennsylvania State University Penn State Heart and Vascular Institute None None None None None None None Francis M. Fesmire Director, Heart-Stroke Center, Assistant Professor None None None None None None None Theodore G. Ganiats University of California San Diego Professor and Interim Chair None None None None None None None A. Michael Lincoff Cleveland Clinic Foundation Cleveland Clinic Lerner College of Medicine Professor of Medicine AstraZeneca Merck None None AstraZeneca Bristol-Myers Squibb Eli Lilly Novartis Pfizer Roche Schering Plough Takeda None None 3.2.1 Eric D. Peterson Duke Clinical Research Institute Duke University Medical Center Professor of Medicine, Director, Cardiovascular Outcomes None None None Eli Lilly Johnson & Johnson None None 3.2.1 George J. Philippides Boston University School of Medicine Associate Professor of Medicine; Associate Chair for Clinical Affairs and Chief Quality Officer, Cardiovascular Section None None None None None None None Pierre Theroux Montreal Heart Institute Professor of Medicine, University of Montreal AstraZeneca Bristol-Myers Squibb Eli Lilly Sanofi Aventis AstraZeneca Boehringer Ingelheim Bristol-Myers Squibb Sanofi Aventis None None Merck None 3.2.1 Nanette K. Wenger Emory University School of Medicine Professor of Medicine (Cardiology) Abbott AstraZeneca Gilead Sciences (formerly CV Therapeutics) Merck Pfizer None None Abbott Eli Lilly Gilead Sciences (formerly CV Therapeutics) Merck Pfizer None None 3.2.1 (Continued) Jneid et al 2012 UA/NSTEMI Focused Update 901 Appendix 1. 